<li>5-htp<p>duloxetine and 5-htp both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>abiraterone<p>abiraterone increases levels of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.</p></li><li>aceclofenac<p>duloxetine, aceclofenac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>acemetacin<p>duloxetine, acemetacin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>almotriptan<p>almotriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>amiodarone<p>amiodarone will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>amphetamine<p>amphetamine increases toxicity of duloxetine by serotonin levels. Use Caution/Monitor. Closely monitor for signs and symptoms of serotonin syndrome (eg, agitation, tremor, tachycardia).</p></li><li>asenapine<p>asenapine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>aspirin<p>duloxetine, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>aspirin rectal<p>duloxetine, aspirin rectal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>duloxetine, aspirin/citric acid/sodium bicarbonate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>atomoxetine<p>duloxetine increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>benazepril<p>duloxetine, benazepril.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.</p></li><li>brexpiprazole<p>duloxetine will increase the level or effect of brexpiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP2D6 inhibitor PLUS a strong/moderate CYP3A4 inhibitor. </p></li><li>buprenorphine subdermal implant<p>duloxetine, buprenorphine subdermal implant.
Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.</p></li><li>bupropion<p>bupropion will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>captopril<p>captopril increases effects of duloxetine by pharmacodynamic synergism. Use Caution/Monitor. Blood pressure lowering drugs may enhance the hypotensive effect of duloxetine. Monitor blood pressure.</p></li><li>celecoxib<p>celecoxib will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>duloxetine, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>choline magnesium trisalicylate<p>duloxetine, choline magnesium trisalicylate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>ciprofloxacin<p>ciprofloxacin will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Coadministration of CYP1A2 inhibiting quinolones with duloxetine may lead to significant increases in duloxetine levels, AUC, and half-life. Consider therapy modification if duloxetine is necessary.</p></li><li>clobazam<p>clobazam will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. </p></li><li>clopidogrel<p>duloxetine increases effects of clopidogrel by pharmacodynamic synergism. Use Caution/Monitor. SNRIs affect platelet activation; coadministration of SNRIs with clopidogrel may increase the risk of bleeding.</p></li><li>cocaine<p>duloxetine and cocaine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>codeine<p>duloxetine decreases effects of codeine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Prevents conversion of codeine to its active metabolite morphine.</p></li><li>cyproheptadine<p>duloxetine increases and cyproheptadine decreases serotonin levels. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.</p></li><li>darifenacin<p>darifenacin will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>deferasirox<p>deferasirox increases levels of duloxetine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>desipramine<p>duloxetine will increase the level or effect of desipramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>desvenlafaxine<p>desvenlafaxine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses &lt;100 mg</p></li><li>dexfenfluramine<p>duloxetine and dexfenfluramine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dextroamphetamine<p>duloxetine will increase the level or effect of dextroamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely.<span><br><br></span>duloxetine and dextroamphetamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dichlorphenamide<p>dichlorphenamide and duloxetine both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>duloxetine, diclofenac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>diflunisal<p>duloxetine, diflunisal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>dihydroergotamine<p>duloxetine and dihydroergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>dihydroergotamine intranasal<p>duloxetine and dihydroergotamine intranasal both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>diphenhydramine<p>diphenhydramine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>eletriptan<p>eletriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>eliglustat<p>eliglustat increases levels of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.</p></li><li>eluxadoline<p>duloxetine increases levels of eluxadoline by affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP1A2 inhibitors.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>ergotamine<p>duloxetine and ergotamine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>esomeprazole<p>esomeprazole will decrease the level or effect of duloxetine by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ethanol<p>ethanol, duloxetine.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive hepatotoxicity.</p></li><li>etodolac<p>duloxetine, etodolac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>etoricoxib<p>duloxetine, etoricoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fenbufen<p>duloxetine, fenbufen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fenfluramine<p>duloxetine and fenfluramine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>fenoprofen<p>duloxetine, fenoprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fesoterodine<p>duloxetine will increase the level or effect of fesoterodine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>flurbiprofen<p>duloxetine, flurbiprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>frovatriptan<p>frovatriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>green tea<p>green tea, duloxetine. Other (see comment). Use Caution/Monitor. 
Comment: Combination may increase risk of bleeding.</p></li><li>hydrocodone<p>duloxetine will increase the level or effect of hydrocodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>hydromorphone<p>duloxetine will increase the level or effect of hydromorphone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>ibuprofen<p>duloxetine, ibuprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>imatinib<p>imatinib will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>imipramine<p>duloxetine will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely.</p></li><li>indomethacin<p>duloxetine, indomethacin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>duloxetine and isoniazid both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>ketoprofen<p>duloxetine, ketoprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>ketorolac<p>duloxetine, ketorolac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>ketorolac intranasal<p>duloxetine, ketorolac intranasal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>l-tryptophan<p>duloxetine and l-tryptophan both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lithium<p>duloxetine and lithium both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lofepramine<p>duloxetine will increase the level or effect of lofepramine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lorcaserin<p>lorcaserin will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lornoxicam<p>duloxetine, lornoxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>lsd<p>duloxetine and lsd both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>lurasidone<p>lurasidone, duloxetine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.</p></li><li>maraviroc<p>maraviroc will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>marijuana<p>marijuana will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>meclofenamate<p>duloxetine, meclofenamate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>mefenamic acid<p>duloxetine, mefenamic acid.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>meloxicam<p>duloxetine, meloxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>methamphetamine<p>duloxetine will increase the level or effect of methamphetamine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely.</p></li><li>metoprolol<p>duloxetine will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mexiletine<p>duloxetine will increase the level or effect of mexiletine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mibefradil<p>duloxetine will increase the level or effect of mibefradil by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>mibefradil will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mirabegron<p>mirabegron will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mirtazapine<p>duloxetine and mirtazapine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>morphine<p>duloxetine will increase the level or effect of morphine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>duloxetine and morphine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>nabumetone<p>duloxetine, nabumetone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>naproxen<p>duloxetine, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>naratriptan<p>naratriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>nebivolol<p>duloxetine will increase the level or effect of nebivolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>nilotinib<p>nilotinib will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>nortriptyline<p>duloxetine will increase the level or effect of nortriptyline by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>oxaprozin<p>duloxetine, oxaprozin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>oxycodone<p>duloxetine will increase the level or effect of oxycodone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>oxymorphone<p>duloxetine will increase the level or effect of oxymorphone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>parecoxib<p>parecoxib will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>duloxetine, parecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>peginterferon alfa 2b<p>peginterferon alfa 2b, duloxetine. Other (see comment). Use Caution/Monitor. 
Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.</p></li><li>pentazocine<p>duloxetine and pentazocine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>pentoxifylline<p>duloxetine will increase the level or effect of pentoxifylline by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>perphenazine<p>perphenazine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>piroxicam<p>duloxetine, piroxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>propafenone<p>duloxetine will increase the level or effect of propafenone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.<span><br><br></span>propafenone will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>propranolol<p>duloxetine will increase the level or effect of propranolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>quinacrine<p>quinacrine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>ranolazine<p>ranolazine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>risperidone<p>duloxetine will increase the level or effect of risperidone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>ritonavir<p>ritonavir will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>rizatriptan<p>rizatriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>salicylates (non-asa)<p>duloxetine, salicylates (non-asa).
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>salsalate<p>duloxetine, salsalate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>same<p>duloxetine and same both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sertindole<p>duloxetine will increase the level or effect of sertindole by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate<p>duloxetine, sodium sulfate/potassium sulfate/magnesium sulfate. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol<p>duloxetine, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sulfasalazine<p>duloxetine, sulfasalazine.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>sulindac<p>duloxetine, sulindac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>sumatriptan<p>sumatriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sumatriptan intranasal<p>sumatriptan intranasal and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>sumatriptan transdermal<p>sumatriptan transdermal and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>tamoxifen<p>duloxetine decreases effects of tamoxifen by decreasing metabolism. Use Caution/Monitor. Inhibition of CYP2D6 metabolism to tamoxifen's active metabolite, endoxifen.</p></li><li>tamsulosin<p>duloxetine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>tapentadol<p>duloxetine and tapentadol both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>teriflunomide<p>teriflunomide decreases levels of duloxetine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>timolol<p>duloxetine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>tolfenamic acid<p>duloxetine, tolfenamic acid.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>tolmetin<p>duloxetine, tolmetin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>tramadol<p>duloxetine and tramadol both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>valerian<p>valerian and duloxetine both increase  sedation. Use Caution/Monitor.</p></li><li>venlafaxine<p>venlafaxine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>vorapaxar<p>duloxetine, vorapaxar.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive antiplatelet effect may occur; SSRIs and SNRIs may cause platelet serotonin depletion .</p></li><li>zolmitriptan<p>zolmitriptan and duloxetine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li>